Jenrry Me-See-Ya; 3rd Failed PED test Leads to Lifelong Ban
On Friday, it was revealed that New York Mets RHP Jenrry Mejia had picked up his third strike.
This tine, however, the strikeout victim...was he, himself.
Mejia, a 26 yard old hard thrower from the Dominican Republic, tested positive for PEDs for the third time in his career, earning him a lifetime ban from baseball. Mejia is the first player in baseball history to be permanently suspended due to PEDs.
Despite the lifetime ban, Mejia has an outside chance of seeing an MLB field again, albeit very slim. He is eligible to apply for reinstatement in one year, but by mandate, must sit out at least two years, making 2018 the first year he could possibly return to the MLB.
Mejia could possibly continue his baseball career on other levels. He is allowed to compete in winter leagues in his home country of the Dominican Republic, which is where he was at the time of his failed third test. Entering the 2016 season, he still had 99 games to go on his 2nd drug related suspension, a 162 game ban. On both the 2nd and 3rd failed tests, Mejia tested for the same banned substance, identified as Boldenone.
Spending his entire career with the Mets, Mejia likely ends his MLB career with an 8-14 record, tallying a 3.83 ERA, striking out 155 while picking up 28 saves. He began his career as a starter, but was moved to the bullpen during the 2014 season, where he eventually grew into the role of New York's closer. It was in 2014 where he tallied all 28 of his saves, which was good for 12th in the National League that season. He was injured in the early stages of the 2015 season, citing elbow inflammation. During this time, he lost the Mets' closer job to Jeurys Familia.
Mejia is the first played banned from the game under the watch of new Commissioner of Baseball, Rob Manfred. Other lifetime banned players include Pete Rose and Shoeless Joe Jackson.
Check out some of Mejia's trademark save celebrations below...
Be the first to know
Want FREE Fantasy and Gaming Advice and Savings Delivered to your Inbox? Sign up for our Newsletter.